TY - JOUR
T1 - Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells
AU - Mizuno, Yuta
AU - Chang, Hsi
AU - Umeda, Katsutsugu
AU - Niwa, Akira
AU - Iwasa, Toru
AU - Awaya, Tomonari
AU - Fukada, So Ichiro
AU - Yamamoto, Hiroshi
AU - Yamanaka, Shinya
AU - Nakahata, Tatsutoshi
AU - Heike, Toshio
PY - 2010/7
Y1 - 2010/7
N2 - Induced pluripotent stem (iPS) cells, which are a type of pluripotent stem cell generated from reprogrammed somatic cells, are expected to have potential for patient-oriented disease investigation, drug screening, toxicity tests, and transplantation therapies. Here, we demonstrated that murine iPS cells have the potential to develop in vitro into skeletal muscle stem/progenitor cells, which are almost equivalent to murine embryonic stem cells. Cells with strong in vitro myogenic potential effectively were enriched by fluorescence-activated cell sorting using the anti-satellite cell antibody SM/C-2.6. Furthermore, on transplantation into mdx mice, SM/C-2.6+ cells exerted sustained myogenic lineage differentiation in injured muscles, while providing long-lived muscle stem cell support. Our data suggest that iPS cells have the potential to be used in clinical treatment of muscular dystrophies.
AB - Induced pluripotent stem (iPS) cells, which are a type of pluripotent stem cell generated from reprogrammed somatic cells, are expected to have potential for patient-oriented disease investigation, drug screening, toxicity tests, and transplantation therapies. Here, we demonstrated that murine iPS cells have the potential to develop in vitro into skeletal muscle stem/progenitor cells, which are almost equivalent to murine embryonic stem cells. Cells with strong in vitro myogenic potential effectively were enriched by fluorescence-activated cell sorting using the anti-satellite cell antibody SM/C-2.6. Furthermore, on transplantation into mdx mice, SM/C-2.6+ cells exerted sustained myogenic lineage differentiation in injured muscles, while providing long-lived muscle stem cell support. Our data suggest that iPS cells have the potential to be used in clinical treatment of muscular dystrophies.
KW - Duchenne muscular dystrophy
KW - High engraftment efficiency
KW - Long-term engraftment
KW - No teratoma formation
KW - Pax7
UR - http://www.scopus.com/inward/record.url?scp=77954448510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954448510&partnerID=8YFLogxK
U2 - 10.1096/fj.09-137174
DO - 10.1096/fj.09-137174
M3 - Article
C2 - 20181939
AN - SCOPUS:77954448510
SN - 0892-6638
VL - 24
SP - 2245
EP - 2253
JO - FASEB Journal
JF - FASEB Journal
IS - 7
ER -